- Nobivac NXT HCPChFeLV combines four live attenuated strains (feline herpesvirus G2620A, calicivirus F9, panleucopenia MW-1, Chlamydia felis Baker) plus self‑amplifying RNA in a replication‑deficient viral replicon particle for FeLV.
- Efficacy assessment included 15 controlled studies and one field trial in 142 cats, showing immunity from about one week post‑vaccination.
- Duration of immunity: 3 years for feline panleucopenia and 1 year for herpesvirus, calicivirus, FeLV and Chlamydia.
- Common adverse events occurred in 1–10% of cats (injection‑site swelling, transient fever); CVMP concluded benefits outweigh risks and recommended EU authorisation.
EMA recommendation
The EMA's veterinary medicines committee (CVMP) recommended EU marketing authorisation for Nobivac NXT HCPChFeLV, the first veterinary vaccine in the EU containing self‑amplifying RNA as an active substance.
Composition
The vaccine combines four live attenuated strains—feline herpesvirus type 1 (G2620A), feline calicivirus (F9), feline panleucopenia (MW‑1) and Chlamydia felis (Baker)—and a replication‑deficient viral replicon particle delivering self‑amplifying RNA encoding a FeLV protein.
Evidence and efficacy
Data came from 15 controlled studies and one field trial in 142 cats; immunity starts about one week after vaccination. Duration of immunity is 3 years for panleucopenia and 1 year for the other four pathogens. Studies showed reduced mortality, clinical signs and pathogen shedding or viraemia across the five targets.
Safety and quality
Common adverse events (1–10% of cats) were transient injection‑site swelling and fever lasting about a day. The vaccine is considered safe for vaccinators and the environment when used per the summary of product characteristics, and manufacturing and batch testing were judged adequate. The CVMP concluded benefits outweigh risks and sent the recommendation to the European Commission for a final decision.
